UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-01

Study Completion Date

2024-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here we intend to assess CIN's performance for hematuria evaluation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Application of UCAD for Diagnosing Urothelial Carcinoma.

NCT03998371

Urothelial Carcinoma Diagnoses Disease Chromosomal Abnormality +1 more

UNKNOWN

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

NCT04943380

Hematuria Urothelial Carcinoma

ACTIVE_NOT_RECRUITING

STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

NCT03988309

Hematuria Urothelial Carcinoma

COMPLETED NA

Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer

NCT00975455

Microscopic or Gross Hematuria

COMPLETED

Investigation of Urinary Biomarkers for the Diagnosis of Insulin Resistance

NCT04010903

Insulin Resistance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hematuria is defined as the presence of 3 or more red blood cells per high-power field (RBC/HPF) under microscopic examination of the urine, which is an important sigh of genitourinary system disease, especially UC. Several methods can be adopted for hematuria evaluation. Cystoscopy is a key component of the hematuria evaluation because it is a reliable way to evaluate the bladder and urethra. Biopsy can also be performed through cystoscopy, making it the "gold standard" for bladder cancer diagnosis. Despite its high reliability and accuracy, it's an invasive examination related with complications such as injury to the urethra, infection, and discomfort. Flat lesions may also be omitted under cystoscopy. Urine cytology is another important method for UC evaluation, but it has a sensitivity of only 15.8%-54.5%.

CIN refers to the ongoing acquisition of genomic alterations, it can range from point mutations to small-scale genomic alterations and gross chromosomal rearrangements. 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN. CIN is presented in UC and it has been adopted as a diagnostic method for UC, such as UroVysion test. Previously, CIN detected by low-coverage whole genome sequencing proved to be a reliable method for UC diagnosis and was named as Urine Exfoliated Cells Copy Number Aberration Detector (UroCAD). In this prospective, multi-canter, observational clinical trial, we intend to assess the possibility of UroCAD as an additional diagnostic tool for hematuria patients by collecting and analyzing 30 ml of urine sample from hematuria patient across 5 centers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematuria Urothelial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hematuria patients

Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria.

urine sample collection

Intervention Type DIAGNOSTIC_TEST

The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.

Non-hematuria patients

Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer.

urine sample collection

Intervention Type DIAGNOSTIC_TEST

The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

urine sample collection

The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants aged ≥ 18 years and signed informed consent form.
* Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:

1. Patients recommended to undergo cystoscopy or ureteroscopy;
2. Patients with treatment-naïve, pathology-confirmed urothelial carcinoma;
3. Patients diagnosed with benign genitourinary disease.
* Participants diagnosed with cancer other than urothelial carcinoma.

Exclusion Criteria

* Participants with history of urothelial carcinoma.
* Participants with urothelial carcinoma accompanied by other malignancy.
* Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor.
* Patients unsuitable for this clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No